Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
ADMA Biologics, Inc. is a biopharmaceutical company specializing in the development and commercialization of plasma-derived therapeutics for immunocompromised patients. Its key products include ASCENIV and BIVIGAM, both FDA-approved intravenous immune globulin therapies. With a growing market projected to exceed $20 billion by 2030, ADMA targets patients with primary immunodeficiency diseases. The company is innovating with a yield enhancement process and expanding its product pipeline to address unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.